R&D channel feed

More pos­i­tive PhI­II da­ta set stage for Scynex­is' vagi­nal yeast in­fec­tion drug ap­proval

6 years ago

Short at­tack tar­gets one of the fa­vorites now shar­ing the lead in the pop­u­lar KRAS drug de­vel­op­ment race

6 years ago

Data­vant boots up a big Covid-19 reg­istry — look­ing to shine a light on virus spread, im­pact and most ef­fec­tive ther­a­pies

6 years ago
Coronavirus

An­oth­er PhI­II win in hand, Cara aims straight for pri­or­i­ty re­view of 'break­through' pru­ri­tus drug

6 years ago

Piv­otal da­ta sug­gest clean safe­ty pro­file, po­ten­cy could set Idor­si­a's sleep­ing pill apart

6 years ago

Ex­elix­is lands PhI­II kid­ney can­cer win with Bris­tol My­ers in their hunt for $4 bil­lion

6 years ago

NIH cor­rals bio­phar­ma com­pa­nies, reg­u­la­tors and tri­al net­works to co­or­di­nate Covid-19 R&D

6 years ago
Coronavirus

Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

6 years ago
Coronavirus

In­ter­im da­ta on Vir's Al­ny­lam-part­nered RNAi hep B drug sug­gest ef­fi­ca­cy is broad­ly on par with J&J, Ar­row­head ri­val — an­a­lysts

6 years ago

Abun­dant fund­ing, sparse da­ta: San Fran­cis­co start­up backs 're­al world' mod­el for rare dis­ease drug de­vel­op­ment

6 years ago
Financing
Startups

Sum­it­o­mo sub­sidiary flash­es new way of treat­ing schiz­o­phre­nia in PhII tri­al

6 years ago

Ex-GSK chief An­drew Wit­ty sum­moned back to the front­lines of vac­cine de­vel­op­ment at em­bat­tled WHO

6 years ago

Gilead takes a hit af­ter a close­ly-watched Covid-19 tri­al of remde­sivir is qui­et­ly ter­mi­nat­ed, rais­ing fresh doubts

6 years ago
Coronavirus

As GSK and Sanofi promise to pro­duce a Covid-19 vac­cine at In­dy 500 speed, some ex­perts start to push back on time­lines

6 years ago
Coronavirus

Mi­cro-cap Mei Phar­ma lands $100M up­front on be­lea­guered PI3K path­way

6 years ago
Deals

Plough­ing through a crowd­ed PD-(L)1 mar­ket, BeiGene loads up on promis­ing lung can­cer da­ta

6 years ago
China
Pharma

Mod­er­na's mis­sion to spear­head a rev­o­lu­tion in vac­cine R&D comes cen­ter stage to­day as the world faces a cru­cial turn­ing point

6 years ago
Coronavirus

Cre­ative or un­eth­i­cal? Re­searchers’ Covid-19 Go­FundMe cam­paign spurs crit­ics

6 years ago
Coronavirus
In Focus

Q&A: An­a­lyst-turned biotech ex­ec-turned an­a­lyst reads the biotech Q1 tea leaves

6 years ago
People
Pharma

As­traZeneca stops lung can­cer tri­al ear­ly, af­ter star drug Tagris­so in­duces 'over­whelm­ing' ef­fi­ca­cy

6 years ago

Judge slaps en­hanced dam­ages on Gilead/Kite for ‘will­ful’ patent vi­o­la­tion, boost­ing award to a block­buster $1.2B — with the me­ter run­ning

6 years ago

A small remde­sivir study with lots of short­com­ings sug­gests it may be work­ing against Covid-19 — and 1 an­a­lyst fore­casts mid-May roll­out

6 years ago
Coronavirus

Nat­ur­al killers are com­ing for Covid-19 and the ther­a­py, ex­perts say, could make things worse

6 years ago
Coronavirus
In Focus

Tan­go Ther­a­peu­tics nabs $60M in CRISPR-based hunt for hid­den can­cer genes

6 years ago
Financing
First page Previous page 205206207208209210211 Next page Last page
A service from the Financial Times